SARS-CoV-2 (COVID-19) Vaccine Industry to Reach $47.5 Billion by 2026 - Initial Revenue Drop Will Occur in 2022, due to Vaccine Pricing Reductions Resulting from Increased Competition

DUBLIN, March 9, 2021 /PRNewswire/ -- The "SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

This report provides a comprehensive overview of the size of the SARS-CoV-2 (COVID-19) Vaccine market, segmentation of the industry (by geography and vaccine technology), key players and the vast potential of vaccines that are in clinical trials.

This analysis indicates that the global COVID-19 vaccine market was worth $59 billion in 2021. However, our forecast indicates that an initial drop will occur in 2022 due to a number of factors including single booster shots as opposed to two shot vaccines and reduced prices in vaccines due to competition.

The COVID vaccine industry is expected to then grow significantly at a CAGR of over 9% and reach $47.5 billion by 2026. This is due to an opening up of the market from a closed government dominated space to one in which private healthcare providers and companies can purchase vaccines. There will also be a continued significant un-met need for vaccine boosters in an endemic situation.

This report describes the evolution of such a huge market in 8 chapters supported by over 74 tables and figures in over 137 pages.

The report focuses on the following:

• An overview of the SARS-CoV2 virus that includes: genetic and structural analysis, mutation and variant characterization
• Global COVID vaccine market, global landscape analysis, vaccine technology breakdown and leading market players
• Advance purchase agreements, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
• Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for COVID vaccines to 2026
• Clinical trial timelines for major vaccines in the pipeline
• Insight into the challenges faced by stakeholders, particularly manufacturers and governments
• Insight into the emergence of variants and their impact on vaccine effectiveness and the overall market
• Financial market forecast through 2026 with CAGR values of all market segments - vaccine technology, geography (US, EU, UK, Japan, RoW) and major players
• Influence of the molecular diagnostics, PCR testing and POC testing landscapes
• Numbers of vaccine doses available by each manufacturer per annum
• Geographical analysis and challenges within countries with respect to advance purchase agreements and distribution channels

Companies Mentioned

• AstraZeneca/Oxford
• Curevac
• J&J
• Moderna
• Novavax
• Pfizer/BioNTech
• Sanofi/GSK

Key Topics Covered

1. Introduction
1.1 Emergence of SARS-CoV2 and the COVID-19 Pandemic
1.2 SARS-CoV-2 Protein and RNA Structure
1.3 SARS-CoV-2 Infection and Immune Response
1.4 SARS-CoV-2 Mutations
1.4.1 B.1.1.7 Variant
1.4.2 B.1.351 Variant
1.4.3 P.1 Variant
1.4.4 Rapid Spread of D614G Mutation Globally
1.4.5 Variants and Vaccine Efficacy
1.4.6 BNT162b2 mRNA Covid-19 Vaccination Effectiveness in Israel
1.4.7 Challenges of Mid-Term and Long-Term Mutations
1.5 Future of Living Alongside SARS-CoV-2

2. COVID Vaccines
2.1 Introduction
2.1.1 mRNA Vaccines
2.1.2 DNA Vaccines
2.1.3 Inactivated Vaccines
2.1.4 Live-Attenuated Vaccines
2.1.5 Recombinant Protein Vaccines
2.1.6 Viral Vector Vaccines
2.2 Pfizer/BioNTech BNT162b2 Vaccine
2.3 Moderna mRNA1273 Vaccine
2.4 CureVac CVnCoV Vaccine
2.5 AstraZeneca/Oxford AZD-1222 Vaccine
2.6 Johnson & Johnson's JNJ-78436735 Vaccine
2.7 Novavax NVX-CoV2373 Vaccine
2.8 Gamaleya Sputnik V Vaccine
2.9 Sinovac Coronavac Vaccin

3. Clinical Trials
3.1 Introduction
3.2 Clinical Trials by Geographic Area
3.3 Clinical Trials by Phase
3.3.1 Phase III COVID Vaccine Trials
3.3.2 Phase II COVID Vaccine Trials
3.3.3 Phase I COVID Vaccine Trials

4. Molecular Diagnostics & PCR Testing
4.1 Introduction
4.2 PCR Diagnostic Testing Has Dominated the Space
4.3 Point of Care Testing

5. Market & Industry Analysis
5.1 Advance Purchase Agreements by Company
5.1.1 Pfizer/BioNTech
5.1.2 Moderna
5.1.3 AstraZeneca/Oxford
5.1.4 Novavax
5.1.5 Sanofi/GSK
5.1.6 J&J
5.1.7 Curevac
5.2 Advance Purchase Agreements - Geographical Breakdown
5.2.1 USA
5.2.2 EU
5.2.2.1 Distribution of Vaccines within the EU
5.2.3 Japan
5.2.4 Australia
5.2.5 China
5.2.6 UK
5.2.7 Russia
5.3 Price of Vaccines
5.4 Reasons for Booster Vaccine Requirements

6. COVID Vaccine Pandemic Market Analysis 2021
6.1 Market Revenue, Volume and Major Players
6.2 SubMarket by Major Player Breakdown
6.3 SubMarket by Technology Type
6.4 SubMarket by Geographical Breakdown

7. COVID Vaccine Market 2022 to 2026
7.1 Endemic Market Forecast to 2026
7.2 SubMarket by Geographical Breakdown to 2026
7.3 SubMarket by Major Player Breakdown to 2026
7.4 SubMarket by Vaccine Technology Breakdown to 2026

8. Future Outlook

For more information about this report visit https://www.researchandmarkets.com/r/kfg4sc

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com